Status:
RECRUITING
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
AbbVie
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, a...
Eligibility Criteria
Inclusion
- Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
- Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
- Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.
Exclusion
- Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
- Known active/symptomatic central nervous system (CNS) metastases should be excluded.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded.
- Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.
Key Trial Info
Start Date :
November 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2031
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT07155174
Start Date
November 25 2025
End Date
September 1 2031
Last Update
December 29 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Ocala Oncology Center /ID# 278269
Ocala, Florida, United States, 34474
2
Fort Wayne Medical Oncology And Hematology /ID# 277336
Fort Wayne, Indiana, United States, 46804
3
Tokyo Metropolitan Komagome Hospital /ID# 277335
Bunkyo Ku, Tokyo, Japan, 113-8677
4
National Cancer Center Hospital /ID# 277237
Chuo-Ku, Tokyo, Japan, 104-0045